Molecular origins of lung cancer: Prospects for personalized prevention and therapy

Journal of Thoracic Oncology

Volumn 5, Issue 6 SUPPL. 3, 2010, Pages

  Haura, Eric B ^a   Camidge, D Ross ^b   Reckamp, Karen ^c   Chiappori, Alberto ^a   Johnson, Faye ^d   Herbst, Roy ^d   Wong, Kwok ^e   Carbone, David ^f  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ALDEHYDE DEHYDROGENASE; ANAPLASTIC LYMPHOMA KINASE; AZD 1480; CARBOPLATIN; CD133 ANTIGEN; CISPLATIN; CP 751871; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; JANUS KINASE; JANUS KINASE INHIBITOR; K RAS PROTEIN; METFORMIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; ONCOLYTIC VIRUS; PACLITAXEL; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN P53; SCATTER FACTOR; SOMATOMEDIN C RECEPTOR; STAT PROTEIN; SUNITINIB; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR NKX2.2; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; VANDETANIB; TUMOR MARKER;

ANGIOGENESIS; BRONCHOSCOPY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; CONFERENCE PAPER; DNA DAMAGE; DNA REPAIR; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; EARLY DIAGNOSIS; EPITHELIAL MESENCHYMAL TRANSITION; FUNDING; GENE AMPLIFICATION; GENETIC ASSOCIATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MOLECULAR BIOLOGY; OVERALL SURVIVAL; PATIENT ADVOCACY; PATIENT EDUCATION; PRIORITY JOURNAL; RISK REDUCTION; RNA SEQUENCE; SIGNAL TRANSDUCTION; SMOKING; THORAX RADIOGRAPHY; THYMUS; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; VESICULAR STOMATITIS VIRUS; ANIMAL; DRUG EFFECT; GENETICS; LUNG TUMOR; PERSONALIZED MEDICINE; PHYSIOLOGY; PRECANCER;

ANIMALS; EARLY DETECTION OF CANCER; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MICRORNAS; NEOPLASTIC STEM CELLS; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953108643     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e2f682     Document Type: Conference Paper

References (20)

1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
2. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
3. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2009.
4. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
5. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 2008;105:19893-19897.
6. Shaw AT, Costa DB, Lafrate AJ, et al. Clinical Activity of the Oral ALK and MET Inhibitor PF-02341066 in Non-Small Cell Lung Cancer (NSCLC) with EML4-ALK Translocations. World Conference on Lung Cancer 2009.
7. Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462:1070-1074.
8. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043.
9. Faber AC, Li D, Song Y, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 2009;106:19503-19508.
10. Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets 2009;10:923-936.
11. Yamamoto N, Mammadova G, Song RX, Fukami Y, Sato K. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells. J Cell Sci 2006;119:4623-4633.
12. Yanagawa J, Walser TC, Zhu LX, et al. Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. Clin Cancer Res 2009;15:6820-6829.
13. Gibbons DL, Lin W, Creighton CJ, et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes and development 2009;23:2140-2151.
14. Nemenoff R, Meyer AM, Hudish TM, et al. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor gamma. Cancer prevention research (Philadelphia, Pa 2008;1:349-356.
15. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008;358:1118-1128.
16. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
17. Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009;16:487-497.
18. Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res 2007;13:4233-4244.
19. Levina V, Marrangoni A, Wang T, et al. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res; 70:338-346.
20. Pine SR, Ryan BM, Varticovski L, Robles AI, Harris CC. Microenvi-ronmental modulation of asymmetric cell division in human lung cancer cells. Proc Natl Acad Sci U S A.